Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Huadong Strikes $1 Billion Deal for Asia Rights to Four ADC Candidates

publication date: Feb 28, 2022

Huadong Medicine will acquire Asia rights (ex-Japan) for two Heidelberg Pharma ADC candidates with options on two more in a deal potentially worth more than $1 billion. The drug rights are worth up to $930 million while Huadong will also purchase 35% of Heidelberg for $118 million. Huadong, which will make a $20 million upfront payment to Heidelberg, is very busy on the deal front currently: last week it entered a $662 million agreement to develop two Kiniksa Pharma anti-inflammatory drug candidates in Southeast Asia. More details....

Stock Symbols: (SHZ: 0963) (FSE: HPHA) (NSDQ: KNSA)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.